Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3225 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Seattle Genetics begins Phase I lymphoma trial

The Phase I study will initially evaluate escalating single-agent doses of SGN-35 administered weekly to patients with relapsed or refractory CD30-positive hematologic malignancies, including Hodgkin lymphoma. Following the